Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 985

BillFederalHouseIn Committee
To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products, so as to enable eligible product developers to develop and test new products, and for other purposes.
About This Bill
Committee
Latest Action · February 5, 2019
Referred to the House Committee on Energy and Commerce.
Introduced
February 5, 2019
Cosponsors (4)
3D 1R
View PDF ↗
SummaryFull TextCommentsAnnotations

Public Comments (0)

No comments yet. Be the first to weigh in from the Take Action box.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.